Sleep Disorders & Research Center Henry Ford Health System, Detroit, Michigan 48202, USA.
Sleep. 2009 Nov;32(11):1513-9. doi: 10.1093/sleep/32.11.1513.
3,4-Methylenedioxymethamphetamine (MDMA) affects monoamine neurotransmitters that play a critical role in sleep and daytime alertness. However, the acute effects of MDMA on sleep and daytime sleepiness have not been studied under placebo-controlled conditions. This study was designed to establish the effects of acute MDMA or placebo administration and sleep restriction on sleep and daytime sleepiness.
Participants with a history of MDMA use were studied on 3 sessions of 3 nights (baseline, treatment, and recovery) and 2 days (following night 2 and 3) per session. On treatment nights (night 2), participants received placebo or 2 mg/kg of MDMA or underwent a restricted bed schedule with placebo. Sleep restriction was a positive control to compare sleep loss and consequent sleepiness associated with MDMA use. The scheduled sleep period was 8 hours long on nonrestricted nights, and standard sleep recordings and daytime sleepiness tests were conducted. Age-matched controls received 1 night and day of standard sleep and daytime sleepiness testing.
Sleep laboratory.
Seven recreational MDMA-users and 13 matched control subjects.
Acute MDMA shortened sleep primarily by increasing sleep latency, and it reduced stage 3/4 sleep and suppressed rapid eye movement (REM) sleep. The MDMA-reduced sleep time was not associated with increased daytime sleepiness the following day, as was seen in the sleep-restriction condition. Compared with control subjects, the MDMA users on the first night in the laboratory had shorter total sleep times and less stage 3/4 sleep. Average daily sleep latency on daytime sleepiness tests the day after nighttime placebo administration was increased in MDMA users compared with the control subjects, and MDMA users had an elevated number of sleep-onset REM periods on these tests, compared with control subjects.
Acute MDMA administration disrupts sleep and REM sleep, specifically, without producing daytime sleepiness such as sleep restriction does. Compared with control subjects, recreational MDMA users showed evidence of hyperarousal and impaired REM function. The mechanism behind these effects is likely due to the deleterious effects of MDMA on catecholamines.
3,4-亚甲基二氧甲基苯丙胺(MDMA)会影响在睡眠和白天警觉中起关键作用的单胺神经递质。然而,在安慰剂对照条件下,尚未研究 MDMA 对睡眠和白天嗜睡的急性影响。本研究旨在确定急性 MDMA 或安慰剂给药和睡眠限制对睡眠和白天嗜睡的影响。
有 MDMA 使用史的参与者在 3 个 3 晚(基线、治疗和恢复)和 2 天(第 2 天和第 3 天之后)的每个阶段进行研究。在治疗夜(第 2 夜),参与者接受安慰剂或 2 毫克/千克的 MDMA 或接受带有安慰剂的受限床位时间表。睡眠限制是一种阳性对照,用于比较与 MDMA 使用相关的睡眠损失和随之而来的嗜睡。非限制夜的预定睡眠时间为 8 小时,并进行标准睡眠记录和白天嗜睡测试。年龄匹配的对照组接受 1 个晚上和白天的标准睡眠和白天嗜睡测试。
睡眠实验室。
7 名娱乐性 MDMA 使用者和 13 名匹配的对照受试者。
急性 MDMA 主要通过增加睡眠潜伏期来缩短睡眠,并且减少了第 3/4 期睡眠并抑制了快速眼动(REM)睡眠。MDMA 减少的睡眠时间与第二天白天嗜睡没有增加有关,就像睡眠限制条件一样。与对照组相比,实验室中的 MDMA 使用者在第一晚的总睡眠时间较短,第 3/4 期睡眠较少。与对照组相比,MDMA 使用者在夜间安慰剂给药后第二天的日间嗜睡测试中平均每日睡眠潜伏期增加,并且与对照组相比,MDMA 使用者在这些测试中出现了更多的睡眠起始 REM 期。
急性 MDMA 给药会破坏睡眠和 REM 睡眠,特别是不会像睡眠限制那样导致白天嗜睡。与对照组相比,娱乐性 MDMA 使用者表现出过度觉醒和 REM 功能受损的证据。这些影响的机制可能归因于 MDMA 对儿茶酚胺的有害影响。